Widely used:Recently Viewed
Clear All$1.25
$-0.05
(-3.85%)
As on 22-Apr-2025 16:00EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
P/E Ratio
--
P/B Ratio
0.96
Industry P/E
36.63
Debt to Equity
0
ROE
-2.85 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-7.85
CFO
$-98.16 Mln
EBITDA
$-103.07 Mln
Net Profit
$-150.97 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sonnet Biotherapeutics Holdings Inc (SONN)
| -14.38 | -9.42 | -18.83 | -91.41 | -88.43 | -84.28 | -75.66 |
|
BSE Sensex*
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Sonnet Biotherapeutics Holdings Inc (SONN)
| -89.32 | -93.12 | -79.97 | -81.61 | -85.46 | -54.26 | -50.76 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 61.50 | 11,346.08 | 26.54 | 8.05 | |
| 64.68 | 6,636.14 | 51.14 | 23.56 | |
| 57.38 | 11,265.03 | 378.67 | 0.76 | |
| 7.69 | 9,036.23 | -- | -3.24 |
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies... fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. Address: 100 Overlook Center, Princeton, NJ, United States, 08540 Read more
Founder, Chairman, CEO & President
Dr. Pankaj Mohan Ph.D.
Founder, Chairman, CEO & President
Dr. Pankaj Mohan Ph.D.
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sonnet Biotherapeutics Holdings Inc (SONN) stood at $ 10 Mln as on 31-Dec-24
The share price of Sonnet Biotherapeutics Holdings Inc (SONN) is $1.25 (NASDAQ) as of 22-Apr-2025 16:00 EDT. Sonnet Biotherapeutics Holdings Inc (SONN) has given a return of -88.43% in the last 3 years.
Sonnet Biotherapeutics Holdings Inc (SONN) has a market capitalisation of $ 4 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Sonnet Biotherapeutics Holdings Inc (SONN) is 0.96 times as on 22-Apr-2025, a 81% discount to its peers’ median range of 4.97 times.
Since, TTM earnings of Sonnet Biotherapeutics Holdings Inc (SONN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sonnet Biotherapeutics Holdings Inc (SONN) and enter the required number of quantities and click on buy to purchase the shares of Sonnet Biotherapeutics Holdings Inc (SONN).
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. Address: 100 Overlook Center, Princeton, NJ, United States, 08540
The CEO & director of Dr. Pankaj Mohan Ph.D.. is Sonnet Biotherapeutics Holdings Inc (SONN), and CFO & Sr. VP is Dr. Pankaj Mohan Ph.D..
There is no promoter pledging in Sonnet Biotherapeutics Holdings Inc (SONN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| Sonnet Biotherapeutics Holdings Inc (SONN) | Ratios |
|---|---|
|
Return on equity(%)
|
-283.39
|
|
Operating margin(%)
|
-957.14
|
|
Net Margin(%)
|
-853.81
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Sonnet Biotherapeutics Holdings Inc (SONN) was $0 Mln.
